New life-changing treatment option fenfluramine recommended for type of rare epilepsy, Lennox–Gastaut syndrome ...
A new treatment option has become available for severe epilepsy: fenfluramine, which is now available on the NHS ...
The drug is the first non-cannabinoid option for patients with LGS and an alternative to Jazz Pharma's Epidyolex (cannabidiol ...
Hundreds of children with severe epilepsy will be able to benefit from a groundbreaking new treatment on the NHS that could significantly reduce their seizures, providing new hope for them and their ...
NICE has approved another epilepsy treatment for Lennox–Gastaut syndrome. Fenfluramine can be used as an add-on to other ...
News Medical on MSN5d
Gene therapy breakthrough offers hope for severe Dravet syndrome casesAAV-Navβ1 gene therapy effectively reduces seizures and prolongs life in a mouse model of SCN1B-linked Dravet syndrome, ...
The partnership splits the rights to Stoke’s epilepsy antisense oligonucleotide, with up to $385 million in potential ...
MONTCO.Today on MSN2d
Plymouth Meeting’s Harmony Biosciences Pivots After FDA Rejects Wakix for Sleep DisorderPlymouth Meeting’s Harmony Biosciences’ stock fell 10% on Wednesday after the FDA rejected the expansion of its insomnia drug ...
Starting today, the National Institute for Health and Care Excellence (NICE) has recommended the funding of fenfluramine for NHS patients in England. This new drug is specifically approved for ...
Encoded Therapeutics is shrinking its headcount by 29% as the gene therapy biotech draws resources away from its early-stage ...
The epilepsy treatment is now approved as an add-on therapy for patients aged ≥ 2 years, following an appeal against NICE’s initial rejection.
Biogen has entered a collaboration with Stoke Therapeutics to develop and and commercialise zorevunersen to treat Dravet syndrome in all territories outside Canada, Mexico and the US. Dravet ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback